• J&J Faces Larger Fine as DOJ Rejects $1B Risperdal Settlement

    Johnson & Johnson's tentative $1 billion settlement with the US Department of Justice over allegations of improper marketing of its schizophrenia drug Risperdal was rejected on 12 March by federal prosecutors, reports The Wall Street Journal . Sources close to the matter told  Bloomberg News  federal prosecutors are demanding an additional $800 million to resolve the civil claims in the government's lawsuit. The charges originate from a US investigation i...
  • OIG Report on Part B Pricing Shows Widespread Violations, Notes Payment Methodology Changes

    The Department of Health and Human Services' (DHHS) Office of the Inspector General (OIG) released a report on 3 January that highlights widespread violations in the reimbursement of pharmaceutical products purchased by the Medicare Part B program. The audit revealed widespread failure to submit complete-or sometimes any-data for approximately 24% of all product codes and 34% of all products. Medicare Part B is a program that administers medical insurance to US citi...